Abstract:Artemisinin and its analogues are currently the most effective anti-malarial drugs. The activation of artemisinin requires the cleavage of the endoperoxide bridge in the presence of iron sources. Once activated, artemisinins attack macromolecules through alkylation and propagate a series of damages, leading to parasite death. Even though several parasite proteins have been reported as artemisinin targets, the exact mechanism of action (MOA) of artemisinin is still controversial and its high potency and specificity against the malaria parasite could not be fully accounted for. Recently, we have developed an unbiased chemical proteomics approach to directly probe the MOA of artemisinin in P. falciparum. We synthesized an artemisinin analogue with an alkyne tag, which can be coupled with biotin through click chemistry. This enabled selective purification and identification of 124 protein targets of artemisinin. Many of these targets are critical for the parasite survival. In vitro assays confirmed the specific artemisinin binding and inhibition of selected targets. We thus postulated that artemisinin kills the parasite through disrupting its biochemical landscape. In addition, we showed that artemisinin activation requires heme, rather than free ferrous iron, by monitoring the extent of protein binding using a fluorescent dye coupled with the alkyne-tagged artemisinin. The extremely high level of heme released from the hemoglobin digestion by the parasite makes artemisinin exceptionally potent against late-stage parasites (trophozoite and schizont stages) compared to parasites at early ring stage, which have low level of heme, mainly derived from endogenous synthesis. Such a unique activation mechanism also confers artemisinin with extremely high specificity against the parasites, while the healthy red blood cells are unaffected. Our results provide a sound explanation of the MOA of artemisinin and its specificity against malaria parasites, which may benefit the optimization of treatment strategies and the battle against the emerging drug resistance.

Facilitated Drug Repurposing with Artemisinin-Derived PROTACs: Unveiling PCLAF as a Therapeutic Target

Design of novel artemisinin-like derivatives with cytotoxic and anti-angiogenic properties

Mechanism-Guided Design and Synthesis of a Mitochondria-Targeting Artemisinin Analogue with Enhanced Anticancer Activity.

Repurposing Artemisinin and its Derivatives as Anticancer Drugs: A Chance or Challenge?

Artemisinin and Its Derivatives as a Repurposing Anticancer Agent: What Else Do We Need to Do?

Ph-Dependent Reversibly Activatable Cell-Penetrating Peptides Improve the Antitumor Effect of Artemisinin-Loaded Liposomes.

Mitochondria-Targeting Artesunate-Rhein Conjugates: Linker-Modulated Cell-Permeability, Heme-Affinity and Anticancer Activity

Discovery of Platinum IV -Artesunate Multiaction Prodrugs as Potent Antitumor and Antimalarial Agents

Chemical Proteomics Approach Reveals the Direct Targets and the Heme-Dependent Activation Mechanism of Artemisinin in Plasmodium Falciparum Using an Artemisinin-Based Activity Probe

Development of artesunate intelligent prodrug liposomes based on mitochondrial targeting strategy

Antitumor Activity of Artemisinin and Its Derivatives: From a Well-Known Antimalarial Agent to a Potential Anticancer Drug

11‐Aza‐artemisinin Derivatives Exhibit Anticancer Activities by Targeting the Fatty Acid Binding Protein 6 (FABP6)

Chemical proteomic profiling with photoaffinity labeling strategy identifies antimalarial targets of artemisinin

Artemisinin Rewires the Protein Interaction Network in Cancer Cells: Network Analysis, Pathway Identification, and Target Prediction

Treatment of Multidrug-Resistant Leukemia Cells by Novel Artemisinin-, Egonol-, and Thymoquinone-Derived Hybrid Compounds

Dual-pharmacophore artezomibs hijack the <i>Plasmodium</i> eubiquitin-proteasome system to kill malaria parasites while overcoming drug resistance

GPX4 Inhibition Synergistically Boosts Mitochondria Targeting Nanoartemisinin-Induced Apoptosis/ferroptosis Combination Cancer Therapy.

Design, synthesis, and in vitro and in vivo biological evaluation of dihydroartemisinin derivatives as potent anti-cancer agents with ferroptosis-inducing and apoptosis-activating properties

Designed, synthesized and biological evaluation of proteolysis targeting chimeras (PROTACs) as AR degraders for prostate cancer treatment

[Design, Synthesis and Antiproliferative Activity in Cancer Cells of Novel Dihydropyrazolyl and Pyrazolyl Artemisinin-Phenyl Ethers].

Structural optimization and biological evaluation for novel artemisinin derivatives against liver and ovarian cancers